Keeley joined atai Life Sciences in early 2022. She has over 15 years of experience in Clinical Operations in the pharma and biotech industry.
Prior to joining atai, Keeley was part of the Clinical Operations Leadership Team at GW Pharmaceuticals. During her time with GW, she worked on the trials that led to the FDA-approval and successful launch of the first cannabinoid-based medicine in the US. Following this, she moved to a leadership position focussing on the early neuro-psychiatry pipeline.
Keeley holds a BSc (Hons) in Animal Science from Imperial College, University of London, and an MSc in Biomedical Science from Leiden University in The Netherlands.